Human epididymis protein 4 (HE4) has emerged as a promising non-invasive biomarker for distinguishing benign endometriotic lesions from malignant transformation, particularly endometriosis-associated ovarian cancer (EAOC). Here, WFDC2 is linked to ovarian cancer.